A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators ...
Apr 18, 2012
0
0
More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the ...
Jun 3, 2016
0
3
Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, the University Medical Center of Regensburg, ...
Jan 29, 2020
0
3
Our immune system must be tremendously complex to respond to the unending assault of viruses, bacteria and cancerous cells. One of the mechanisms used by the immune system to cope with the huge variety of possible threats ...
Oct 22, 2012
0
0
(HealthDay)—A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests.
Jan 9, 2014
0
0
Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type ...
Feb 13, 2015
0
7
Death from infection—the leading cause of death for patients with a common type of leukemia—is linked to specific gene mutations, a new study has found.
Apr 8, 2021
0
9
Researchers from the Centre for Genomic Regulation (CRG) in Barcelona reprogramme lymphoma and leukaemia cells to halt their malignancy. Resulting cells remain benign even when no longer subjected to treatment and reduce ...
Apr 3, 2013
0
0
The antibody response to immune threats is managed by cells known as B lymphocytes. The differentiation and function of B cells are tightly regulated to ensure a prompt response to confirmed dangers, such as viruses or bacteria, ...
Nov 21, 2012
0
0
The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center—Arthur ...
Jul 21, 2021
0
1
